Lifeward Ltd. LFWD
are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical
rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community.
Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord
injury ("SCI Products"). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use
Last close
6.06
2026-10-23
Market cap
$17.2M
2026-06-30 share count
52-week range
4.14 - 9.61
Valuation FY2025 figures against the last close
P/S12.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-17.16
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $25.7M | $13.9M | $5.5M | $6.0M | $4.4M | $4.9M | $6.5M | $7.8M | $5.9M |
| Cost of revenue | $13.6M | $17.4M | $9.4M | $3.6M | $3.1M | $2.2M | $2.1M | $3.7M | $4.7M | $5.1M |
| Gross profit | $8.4M | $8.2M | $4.5M | $1.9M | $2.9M | $2.2M | $2.7M | $2.8M | $3.1M | $736.0K |
| R&D | $3.2M | $4.6M | $4.1M | $4.0M | $2.9M | $3.5M | $5.3M | $7.3M | $6.0M | $9.0M |
| SG&A | $8.2M | $5.2M | $10.0M | $7.1M | $5.6M | $5.0M | $5.3M | $6.8M | $7.7M | $8.2M |
| Total operating expenses | $28.1M | $37.6M | $28.1M | $21.0M | $15.6M | $14.2M | $16.8M | $22.0M | $25.1M | $31.2M |
| Operating income | -$19.7M | -$29.3M | -$23.6M | -$19.1M | -$12.7M | -$12.0M | -$14.0M | -$19.2M | -$22.0M | -$30.4M |
| Interest expense | $312.0K | $643.0K | $1.4M | $0 | $0 | — | — | — | — | — |
| Pre-tax income | -$20.0M | -$28.9M | -$22.1M | -$19.1M | -$12.6M | -$12.9M | -$15.5M | -$21.7M | -$24.6M | -$32.5M |
| Income tax | $55.0K | $43.0K | $12.0K | $467.0K | $94.0K | $51.0K | $7.0K | $5.0K | $119.0K | $3.0K |
| Net income | -$19.9M | -$28.9M | -$22.1M | -$19.6M | -$12.7M | -$13.0M | -$15.6M | -$21.7M | -$24.7M | -$32.5M |
| EPS, basic | -17.16 | -39.96 | -31.13 | -2.20 | -0.27 | -0.82 | — | — | — | — |
| EPS, diluted | -17.16 | -39.96 | -31.13 | -2.20 | -0.27 | -0.82 | -2.70 | -14.72 | -30.57 | -2.47 |
| Shares, diluted (wtd. avg.) | 1.2M | 724,272 | 710,941 | 8.9M | 47.9M | 15.8M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.2M | $6.7M | $28.8M | $68.6M | $89.0M | $21.1M | $17.0M | $10.3M | $15.4M | $24.5M |
| Receivables | $6.1M | $6.0M | $3.1M | $1.0M | $585.0K | $684.0K | $794.0K | $758.0K | $1.1M | $1.3M |
| Inventory | $5.7M | $6.7M | $5.7M | $2.9M | $3.0M | $3.5M | $3.1M | $2.2M | $3.6M | $3.3M |
| Total current assets | $15.8M | $21.3M | $39.2M | $72.5M | $92.5M | $25.2M | $21.1M | $13.2M | $20.9M | $29.3M |
| Property, plant and equipment | $585.0K | $867.0K | $1.3M | $196.0K | $284.0K | $437.0K | $501.0K | $626.0K | $840.0K | $1.3M |
| Goodwill | $4.8M | $7.5M | $7.5M | $0 | — | — | — | — | — | — |
| Other intangibles | — | $0 | $12.5M | — | — | — | — | — | — | — |
| Total assets | $22.9M | $30.5M | $63.2M | $74.2M | $94.8M | $28.1M | $24.4M | $15.0M | $22.9M | $31.8M |
| Accounts payable | $5.6M | $5.0M | $5.1M | $1.9M | $1.4M | $2.3M | $2.7M | $2.3M | $1.8M | $3.4M |
| Short-term debt | — | — | — | — | — | — | $5.4M | $1.7M | $6.4M | $7.5M |
| Total current liabilities | $12.0M | $10.2M | $11.8M | $4.8M | $4.0M | $4.7M | $10.2M | $5.4M | $9.7M | $12.4M |
| Long-term debt | — | — | — | — | — | — | $1.5M | $7.0M | $8.9M | $10.5M |
| Total liabilities | $14.5M | $11.6M | $16.7M | $6.1M | $5.4M | $6.3M | $13.6M | $13.0M | $19.2M | $23.5M |
| Retained earnings | -$284.7M | -$264.8M | -$235.9M | -$213.8M | -$194.2M | -$181.4M | -$168.5M | -$152.9M | -$131.2M | -$106.5M |
| Total equity | $8.4M | $18.8M | $46.5M | $68.2M | $89.4M | $21.8M | $10.8M | $1.9M | $3.7M | $8.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.8M | -$21.7M | -$20.7M | -$17.9M | -$11.5M | -$12.6M | -$14.8M | -$14.8M | -$22.5M | -$26.7M |
| Depreciation and amortisation | $333.0K | $494.0K | $239.0K | $202.0K | $266.0K | $285.0K | $321.0K | $463.0K | $642.0K | $696.0K |
| Stock-based compensation | $743.0K | $1.3M | $1.3M | $993.0K | $833.0K | $749.0K | $1.1M | $2.8M | $3.7M | $3.4M |
| Capital expenditure | $16.0K | $0 | $81.0K | $25.0K | $47.0K | $73.0K | $22.0K | $13.0K | $21.0K | $452.0K |
| Investing cash flow | -$16.0K | $0 | -$18.1M | -$25.0K | -$47.0K | -$73.0K | -$22.0K | -$13.0K | -$21.0K | -$437.0K |
| Financing cash flow | $12.2M | $0 | -$992.0K | -$2.5M | $79.5M | $16.7M | $21.5M | $9.7M | $13.4M | $33.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001208.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $7.8M | $6.5M | $4.9M | $4.4M | $6.0M | $5.5M | $13.9M | $25.7M | $1.4M |
| Gross profit | $736.0K | $3.1M | $2.8M | $2.7M | $2.2M | $2.9M | $1.9M | $4.5M | $8.2M | $8.4M |
| Net income | -$32.5M | -$24.7M | -$21.7M | -$15.6M | -$13.0M | -$12.7M | -$19.6M | -$22.1M | -$28.9M | -$19.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Officer or director change Item 5.02
- Other event Item 8.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.78B | 57.5x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.34B | 48.7x | 11.5% |
| STE | STERIS plc | $22.63B | 29.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.80B | 27.8x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.98B | 27.3x | 0.9% |
| MSA | MSA Safety Inc | $7.03B | 25.7x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.90B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.28B | 29.4x | 7.5% |